Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-inflammatory Therapy in TPIAT
NCT02713997Phase 4Completed
- Sponsor
- University of Minnesota
- Start
- Dec 2016
- Primary completion
- Jul 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of etanercept, alpha-1-proteinase inhibitor in diabetes mellitus (DM), sponsored by University of Minnesota. Started Dec 2016; status: completed.
02
Drugs
etanerceptalpha-1-proteinase inhibitor
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT02713997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02713997.